Roche's 9M 2026 sales rise on strong drug demand, pipeline advances
FROM THE WIRE · FINANCE.YAHOO.COM
Swiss pharma giant Roche Holding AG RHHBY reported sales of CHF 46.5 billion in the first nine months of 2026, up 1% year over year. Sales were up 6% at constant exchange rates (CER). The company reports under two divisions — Pharmaceuticals and Diagnostics. All growth rates…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishRevenue growth at a major pharma company supports the sector, and the stock is already up year to date.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Roche reported sales of CHF 46.5 billion in the first nine months of 2026, up 1% year over year.
- 02Sales were up 6% at constant exchange rates.
- 03The Pharmaceuticals division grew 7% to CHF 36.2 billion, driven by Xolair, Hemlibra, Ocrevus, Phesgo and Vabysmo.
- 04The Diagnostics division rose 4% to CHF 10.3 billion; shares are up 16.9% year to date.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Roche Holding AG392.10 CHFMarket closedtoday +0.03%Positive Roche Holding AG59.74 USD-0.07%today +1.07%Positive
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets